Scholarlink

Background <p>Patients with non–germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL) often exhibit suboptimal responses to standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy.</p> Methods <p>This multicenter, phase II study evaluated the safety and efficacy of zanubrutinib, lenalidomide, and R-CHOP (ZR2-CHOP) in newly diagnosed non-GCB DLBCL. Patients received oral zanubrutinib (160&#xa0;mg twice daily), lenalidomide (25&#xa0;mg once daily on Days 1–7), and standard R-CHOP every 21&#xa0;days for up to six cycles.</p> Results <p>A total of 34 patients were enrolled. The median age was 55&#xa0;years, with 29.4% over 60&#xa0;years. Double-expressor lymphoma (DEL) was present in 64.7%, and 39.3% were classified as the MCD genetic subtype. The best overall response rate was 100%. Complete response (CR) was achieved in 70.6% of patients at mid-treatment and 94.1% at end-of-treatment. With a median follow-up of 28&#xa0;months, the 2-year progression-free survival (PFS) rate was 84.8%, and the 2-year overall survival (OS) rate was 96.8%. In this small cohort, PFS benefit appeared consistent across high-risk subgroups, including those with DEL and MCD subtypes. Plasma ctDNA negativity was achieved in 84% (21/25) of evaluable patients during treatment. Grade 3–4 adverse events occurred in 67.6% of patients, primarily hematologic toxicities.</p> Conclusions <p>ZR2-CHOP demonstrated promising efficacy and manageable toxicity in newly diagnosed non-GCB DLBCL.</p> Trial registration <p>ClinicalTrials.gov Identifier: NCT05200312 (registered January 20, 2022).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Zanubrutinib, lenalidomide and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in non–germinal center B-cell diffuse large B-cell lymphoma: a multi-center phase 2 study by Jiangsu Cooperative Lymphoma Group (JCLG)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月24日

查看全文
  • Yi Xia,
  • Yi Miao,
  • Siqi Qian,
  • Run Zhang,
  • Shuchao Qin,
  • Xiaoyan Xie,
  • Bingzong Li,
  • Yeqin Sha,
  • Hanning Tang,
  • Hui Jin,
  • Lei Cao,
  • Wei Xu,
  • Lei Fan,
  • Jianyong Li,
  • Wenyu Shi,
  • Huayuan Zhu

摘要

Background

Patients with non–germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL) often exhibit suboptimal responses to standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy.

Methods

This multicenter, phase II study evaluated the safety and efficacy of zanubrutinib, lenalidomide, and R-CHOP (ZR2-CHOP) in newly diagnosed non-GCB DLBCL. Patients received oral zanubrutinib (160 mg twice daily), lenalidomide (25 mg once daily on Days 1–7), and standard R-CHOP every 21 days for up to six cycles.

Results

A total of 34 patients were enrolled. The median age was 55 years, with 29.4% over 60 years. Double-expressor lymphoma (DEL) was present in 64.7%, and 39.3% were classified as the MCD genetic subtype. The best overall response rate was 100%. Complete response (CR) was achieved in 70.6% of patients at mid-treatment and 94.1% at end-of-treatment. With a median follow-up of 28 months, the 2-year progression-free survival (PFS) rate was 84.8%, and the 2-year overall survival (OS) rate was 96.8%. In this small cohort, PFS benefit appeared consistent across high-risk subgroups, including those with DEL and MCD subtypes. Plasma ctDNA negativity was achieved in 84% (21/25) of evaluable patients during treatment. Grade 3–4 adverse events occurred in 67.6% of patients, primarily hematologic toxicities.

Conclusions

ZR2-CHOP demonstrated promising efficacy and manageable toxicity in newly diagnosed non-GCB DLBCL.

Trial registration

ClinicalTrials.gov Identifier: NCT05200312 (registered January 20, 2022).